Special Autumn 2025Preview: CROs & CDMOsCDMOs and CROs are under great pressure to integrate new trial designs and drug formats – including ATMPs, ADCs, condensate blockers, RNA drugs and formulations as well as automated preclinical testing … more ➔
Special Autumn 2025Preview: Automation & Data ScienceEuropean Biotechnology Magazine’s comprehensive special feature ‘Lab automation & data sciences/AI’, created in cooperation with the Society for Laboratory Automation and Screening (SLAS), provides … more ➔
Special Autumn 2025Preview: ADCs & beyondAntibody-drug conjugates and targeted radiopharmaceuticals promised chemotherapies and radiotherapies with fewer side effects by delivering cytotoxic cargos more specifically to the site of action, usually … more ➔
Special Summer 2025Preview: (Bio)EngineeringUsing engineered organisms for chemical manufacturing was the initial foundation motivation for Genentech in 1976 in South San Francisco. However, pharmaceutical manufacturing in recombinant bacteria … more ➔
Special Summer 2025Preview: Clusters + ManufacturingAs the European biotech ecosystem is increasingly maturing compared to competitors from Asia and the US, European Biotechnology Magazine takes a closer look at the relevant but also specialised life … more ➔
Special Summer 2025Preview: New ModalitiesHot topics in automated screening and expression of new modalities: Whether antibody conjugates (ADCs or radiopharmaceuticals), T-cell, NK-cell or MAIT engagers, bispecific checkpoint inhibitors, molecular … more ➔
Special Spring 2025Preview: Legal, Tax + AccountingIP, market studies, finance expertise: Companies need external expertise from consulting firms and commercial law firms. For biotech start-ups, IP rights and good legal advice are often the only assets … more ➔
Special Spring 2025Preview: Technology + System IntegrationThe integration of licensed, newly developed technologies into automated environments used by established laboratory equipment suppliers and drug screening service providers is driving progress in drug … more ➔
Special Spring 2025Preview: Oligos and PeptidesHot topics in oligonucleotide & peptide design, analytics and manufacturing:RNA and peptide drugs, such as the new GLP1 receptor agonists, are the rising stars after the COVID-19 pandemic. A US$125bn … more ➔
Special Winter 2024Protein Engineering and ServicesMonoclonal antibodies still dominate the US$417bn biologics market. After decades of development, however, improved antibodies and protein formats with better target selectivity and safety profiles … more ➔
